Xencor Inc (XNCR) stock
XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30194% above fair value
$34.39−0.11 (-0.32%)
Close on Nov 18, 2026Market cap $2.56BP/E –Yield –
Xencor price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Xencor's price to sales ratio was 28.3× on Nov 11, 2026, against 8.2× a year earlier. Over the last 5 years it ranged from 3.9× to 28.3×, with a median of 7.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 28.3× | +21.0 |
| 2025 | Dec 31, 2025 | 7.3× | −7.5 |
| 2024 | Dec 31, 2024 | 14.8× | +5.9 |
| 2023 | Dec 29, 2023 | 8.9× | +3.6 |
| 2022 | Dec 30, 2022 | 5.2× | −9.2 |
| 2021 | Dec 31, 2021 | 14.4× | −15.3 |
| 2020 | Dec 31, 2020 | 29.7× | +17.8 |
| 2019 | Dec 31, 2019 | 11.8× | −17.7 |
| 2018 | Apr 30, 2018 | 29.5× | – |
See a number that looks wrong?